July 2004 Table of Contents

External Link - article-102206.pdf

Articles in this issue

almost 22 years ago

Article

One World, One Voice

almost 22 years ago

Article

Pricing Climate Heats Up in US and Europe

almost 22 years ago

Article

Stop Giving Away Your Secrets

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

From Dashboards to Decisions: How AI Is Reshaping Pharma Brand Strategy

ByLuke Greenwalt

June 9th 2026

CMS ACCESS Model: Changing the Landscape of Disease Management

ByIra Studin, PhD

June 9th 2026

Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion

ByNicholas Jacobus

June 9th 2026

Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering

ByNicholas Jacobus

June 9th 2026

GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.

ByNicholas Jacobus

June 9th 2026

July 2004 Table of Contents

Articles in this issue

Related Content

From Dashboards to Decisions: How AI Is Reshaping Pharma Brand Strategy

CMS ACCESS Model: Changing the Landscape of Disease Management

Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion

Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering

GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.

Trending on PharmExec

Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner

GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.

Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering

Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion

Right–to-Try Does Not Undermine Clinical Trials